NYSE:VOR Vor Biopharma (VOR) Stock Price, News & Analysis → Banking Apocalypse Ahead: Secure Your Savings Today! (From Weiss Ratings) (Ad) Free VOR Stock Alerts $1.31 -0.01 (-0.76%) (As of 06/5/2024 ET) Add Compare Share Share Today's Range$1.29▼$1.3650-Day Range$1.31▼$2.3752-Week Range$1.25▼$5.70Volume178,794 shsAverage Volume301,900 shsMarket Capitalization$89.42 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Vor Biopharma alerts: Email Address Vor Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside854.2% Upside$12.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 5 Articles This WeekInsider TradingSelling Shares$20,357 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.49) to ($1.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.34 out of 5 starsMedical Sector283rd out of 904 stocks 4.5 Analyst's Opinion Consensus RatingVor Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVor Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vor Biopharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VOR. Previous Next 0.0 Dividend Strength Dividend YieldVor Biopharma does not currently pay a dividend.Dividend GrowthVor Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VOR. Previous Next 3.1 News and Social Media Coverage News SentimentVor Biopharma has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vor Biopharma this week, compared to 1 article on an average week.Search Interest13 people have searched for VOR on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.MarketBeat Follows4 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vor Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,357.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Vor Biopharma is held by insiders.Percentage Held by Institutions97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vor Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vor Biopharma are expected to grow in the coming year, from ($1.49) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vor Biopharma is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vor Biopharma is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Vor Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad OIC[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.Click here to register now. About Vor Biopharma Stock (NYSE:VOR)Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More VOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VOR Stock News HeadlinesJune 5 at 6:40 AM | insidertrades.comInsider Selling: Vor Biopharma Inc. (NYSE:VOR) Insider Sells 14,645 Shares of StockJune 4 at 4:01 PM | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 28, 2024 | finanznachrichten.deBio-Thera Solutions, Ltd: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UKMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma Amid Promising Clinical Trials and Market Potential ExpansionMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Vor Biopharma’s Clinical and Financial FortitudeMay 11, 2024 | markets.businessinsider.comSilvan Tuerkcan Reaffirms Buy Rating for Vor Biopharma Citing Clinical Progress and Expanding Market PotentialMay 10, 2024 | markets.businessinsider.comPromising Clinical Trials and Stable Financial Outlook Bolster Buy Rating for Vor BiopharmaMay 9, 2024 | msn.comVOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024May 9, 2024 | globenewswire.comVor Bio Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 6, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMay 3, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comVor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of DirectorsApril 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma on Clinical Progress and Market PotentialApril 1, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMarch 29, 2024 | finance.yahoo.comHere's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn SituationMarch 28, 2024 | investorplace.comThe Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessMarch 26, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)March 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)March 22, 2024 | finanznachrichten.deVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 21, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)March 20, 2024 | benzinga.comVor Biopharma: Q4 Earnings InsightsMarch 20, 2024 | finance.yahoo.comVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 20, 2024 | globenewswire.comVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 19, 2024 | msn.comIntellia Therapeutics doses first patient in pivotal in vivo CRISPR trialMarch 16, 2024 | finance.yahoo.comVOR Apr 2024 5.000 callSee More Headlines Receive VOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/05/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry N/A Sub-IndustryN/A Current SymbolNYSE:VOR CUSIPN/A CIK1817229 Webwww.vorbiopharma.com Phone617-655-6580FaxN/AEmployees168Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$17.50 Low Stock Price Target$10.00 Potential Upside/Downside+854.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares68,260,000Free Float65,052,000Market Cap$89.42 million OptionableNot Optionable Beta-0.29 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Robert Ang M.B.A. (Age 49)M.D., MBBS, President, CEO & Director Comp: $943.91kDr. Tirtha Chakraborty Ph.D. (Age 51)Chief Scientific Officer Comp: $661.98kDr. Eyal C. Attar M.D. (Age 53)Chief Medical Officer Comp: $660.55kDr. Siddhartha Mukherjee DPHIL (Age 53)M.D., Ph.D., Scientific Founder & Chairman of Scientific Advisory Board Dr. Nathan D. Jorgensen M.B.A. (Age 47)Ph.D., Chief Financial Officer Comp: $608.48kMs. Tania Philipp (Age 52)Chief People Officer Mr. John C. King M.B.A. (Age 48)Chief Commercial Officer Mr. Samir Vattompadam M.S.Senior Vice President of Portfolio Strategy & Program ManagementMr. David Phillips M.B.A.Senior VP & Head of QualityMore ExecutivesKey CompetitorsSNDLNASDAQ:SNDLOrganogenesisNASDAQ:ORGOAura BiosciencesNASDAQ:AURAGlobal Cord BloodNYSE:COVerrica PharmaceuticalsNASDAQ:VRCAView All CompetitorsInsiders & InstitutionsEyal C AttarSold 14,645 sharesTotal: $20,356.55 ($1.39/share)Artal Group S.A.Sold 1,347,424 shares on 5/17/2024Ownership: 1.465%Vanguard Group Inc.Bought 69,436 shares on 5/10/2024Ownership: 2.657%Acadian Asset Management LLCBought 53,708 shares on 5/10/2024Ownership: 0.079%SG Americas Securities LLCSold 8,114 shares on 5/7/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions VOR Stock Analysis - Frequently Asked Questions Should I buy or sell Vor Biopharma stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vor Biopharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VOR shares. View VOR analyst ratings or view top-rated stocks. What is Vor Biopharma's stock price target for 2024? 5 equities research analysts have issued 12-month price objectives for Vor Biopharma's stock. Their VOR share price targets range from $10.00 to $17.50. On average, they expect the company's stock price to reach $12.50 in the next year. This suggests a possible upside of 854.2% from the stock's current price. View analysts price targets for VOR or view top-rated stocks among Wall Street analysts. How have VOR shares performed in 2024? Vor Biopharma's stock was trading at $2.25 at the beginning of 2024. Since then, VOR stock has decreased by 41.8% and is now trading at $1.31. View the best growth stocks for 2024 here. When is Vor Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our VOR earnings forecast. How were Vor Biopharma's earnings last quarter? Vor Biopharma Inc. (NYSE:VOR) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.08. What ETFs hold Vor Biopharma's stock? ETFs with the largest weight of Vor Biopharma (NYSE:VOR) stock in their portfolio include Loncar China Biopharma ETF (CHNA).Range Cancer Therapeutics ETF (CNCR). When did Vor Biopharma IPO? Vor Biopharma (VOR) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO. Who are Vor Biopharma's major shareholders? Vor Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.66%), Artal Group S.A. (1.46%), Acadian Asset Management LLC (0.08%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Eyal C Attar and Ventures Vi LP 5Am. View institutional ownership trends. How do I buy shares of Vor Biopharma? Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:VOR) was last updated on 6/6/2024 by MarketBeat.com Staff From Our Partners"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Phar...Behind the Markets | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBitcoin’s Biggest Year Yet2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my...Paradigm Press | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the big...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.